From b8fd0d36dd71f4dd754c8b7141a0057968d2700f Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 4 May 2026 04:23:45 +0000 Subject: [PATCH] vida: extract claims from 2025-xx-pmc-glp1-psychiatric-disproportionality-faers-cvarod-daen - Source: inbox/queue/2025-xx-pmc-glp1-psychiatric-disproportionality-faers-cvarod-daen.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...ubtype-specific-protective-bed-harmful-restrictive.md | 7 +++++++ ...lcohol-use-disorder-in-comorbid-obesity-population.md | 9 ++++++++- ...1-psychiatric-disproportionality-faers-cvarod-daen.md | 5 ++++- 3 files changed, 19 insertions(+), 2 deletions(-) rename inbox/{queue => archive/health}/2025-xx-pmc-glp1-psychiatric-disproportionality-faers-cvarod-daen.md (97%) diff --git a/domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md b/domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md index d2ac1ab03..5b512c86b 100644 --- a/domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md +++ b/domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md @@ -17,3 +17,10 @@ related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesoli # GLP-1 eating disorder risk is subtype-specific: protective for binge eating disorder but potentially harmful for restrictive eating disorders through the same appetite suppression mechanism This review establishes that GLP-1 receptor agonists create opposing clinical outcomes across eating disorder subtypes through a single pharmacological mechanism. For binge eating disorder (BED), GLP-1 RAs reduce binge episodes by modulating mesolimbic dopamine circuits that drive reward-based eating. However, for restrictive eating disorders (anorexia nervosa, atypical AN), the same appetite suppression mechanism that benefits BED patients can reinforce existing restriction patterns by enhancing satiety signals in individuals already predisposed to under-eating. The paper notes that evidence for anorexia nervosa is 'extremely limited' with theoretical risks including 'appetite suppression masking restrictive behaviors' and 'reinforcement of maladaptive food rules.' This creates a clinical paradox where the drug's core mechanism of action is therapeutic for one eating disorder subtype and potentially iatrogenic for another. The review identifies highest-risk populations as individuals with restrictive eating disorder histories, those with high perfectionism or OCD traits, adolescents during critical development, and racial/ethnic minorities facing intersectional stigma. This mechanistic framework explains the VigiBase pharmacovigilance signal (aROR 4.17-6.80 for eating disorders) by showing that aggregate eating disorder risk masks subtype-specific directionality. + + +## Challenging Evidence + +**Source:** PMC12630159, cross-national pharmacovigilance with indication bias caveat + +Australian DAEN database shows extremely elevated eating disorder ROR of 17.66 for dulaglutide, suggesting the signal may be stronger than previously estimated or that certain populations show higher susceptibility. The discrepancy between this study's ROR (1.47-1.58) and VigiBase aROR (4.17-6.80) indicates methodological choices significantly affect signal magnitude. Researchers acknowledge fundamental limitation: 'databases used in this study did not contain information on any pre-existing psychiatric conditions' making it impossible to 'distinguish between a medicine-induced reaction and an event related to a patient's ongoing health issues.' This challenges the certainty of subtype-specific risk stratification when indication bias cannot be controlled. diff --git a/domains/health/glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population.md b/domains/health/glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population.md index 0ccb60995..751b1d0d2 100644 --- a/domains/health/glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population.md +++ b/domains/health/glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population.md @@ -12,7 +12,7 @@ scope: causal sourcer: NIH / JAMA Psychiatry supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"] challenges: ["the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access"] -related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"] +related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients"] --- # GLP-1 receptor agonists demonstrate NNT 4.3 for alcohol use disorder in adults with comorbid obesity — superior to all approved AUD medications @@ -39,3 +39,10 @@ Meta-analysis demonstrates effect extends beyond comorbid obesity population to **Source:** VigiBase study, Clinical Nutrition 2025 VigiBase pharmacovigilance analysis shows eating disorder signals with aROR 4.17-6.80 across all three GLP-1 RAs (semaglutide, dulaglutide, liraglutide), suggesting GLP-1's appetite suppression mechanism may precipitate eating disorder pathology in vulnerable individuals. This is a class effect, not drug-specific, indicating the reward pathway modulation that benefits AUD may create eating disorder risk in susceptible populations. + + +## Extending Evidence + +**Source:** PMC12630159, 2025 multi-database disproportionality analysis + +Cross-national pharmacovigilance analysis across FAERS (US), CVAROD (Canada), and DAEN (Australia) confirms eating disorder signal for GLP-1 agonists. Dulaglutide shows ROR 1.47 (95%CI 1.26-1.71) in FAERS and dramatically elevated ROR 17.66 (95%CI 2.45-127.37) in Australian DAEN. Tirzepatide shows ROR 1.58 (95%CI 1.14-2.20) in FAERS. However, these ROR values are substantially lower than VigiBase aROR (4.17-6.80), likely due to methodological differences: this study uses unadjusted ROR while VigiBase uses adjusted analysis controlling for co-reported adverse events. The cross-national consistency increases biological plausibility of the eating disorder signal, though researchers explicitly note they 'cannot determine a causal relationship between medication use and AEs' due to indication bias (databases lack pre-existing psychiatric condition data). diff --git a/inbox/queue/2025-xx-pmc-glp1-psychiatric-disproportionality-faers-cvarod-daen.md b/inbox/archive/health/2025-xx-pmc-glp1-psychiatric-disproportionality-faers-cvarod-daen.md similarity index 97% rename from inbox/queue/2025-xx-pmc-glp1-psychiatric-disproportionality-faers-cvarod-daen.md rename to inbox/archive/health/2025-xx-pmc-glp1-psychiatric-disproportionality-faers-cvarod-daen.md index f13d16497..eeb82bbd5 100644 --- a/inbox/queue/2025-xx-pmc-glp1-psychiatric-disproportionality-faers-cvarod-daen.md +++ b/inbox/archive/health/2025-xx-pmc-glp1-psychiatric-disproportionality-faers-cvarod-daen.md @@ -7,10 +7,13 @@ date: 2025-01-01 domain: health secondary_domains: [] format: paper -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-05-04 priority: medium tags: [glp1, pharmacovigilance, eating-disorders, faers, disproportionality, psychiatric-adverse-events, cross-national] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content